Drug Trial Radar · NCT02449291
Study of APD421 as PONV Treatment (no Prior Prophylaxis)
Last checked: Nov 20, 2026Latest source record: Jan 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
568
Actual
Start
Sep 2015
Primary completion
Jul 2016
Study completion Jul 2016
Sponsor
- Lead sponsor
- Acacia Pharma LtdIndustry
- Sponsor type
- Industry
- First posted
- May 20, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have not had prior PONV prophylaxis.
Conditions
- Postoperative Nausea and Vomiting
Interventions
APD421Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Response (Success of Initial PONV Treatment)Time frame: 0-24 hours after treatment
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
Jackson Memorial Hospital
Miami, Florida
Ohio State University
Columbus, Ohio
CHU de Hautepierre
Strasbourg, France
Universität Heidelberg
Heidelberg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.